What is the concise management plan for stable angina for exam purposes?

Management of Stable Angina: Exam-Ready Summary

All patients with stable angina require aspirin 75 mg daily, high-intensity statin therapy, a beta-blocker as first-line anti-anginal therapy, and sublingual nitroglycerin for acute symptom relief. 1, 2

Immediate Pharmacological Foundation (Class I Recommendations)

Mortality-Reducing Medications (Mandatory)

• Aspirin 75–100 mg daily for all patients without contraindications (active GI bleeding, aspirin allergy) 3, 1, 2
• Clopidogrel 75 mg daily only if aspirin is absolutely contraindicated 3, 2
• High-intensity statin therapy for every patient regardless of baseline LDL, targeting LDL <70 mg/dL 3, 1, 2
• ACE inhibitor for patients with hypertension, diabetes, heart failure, LV dysfunction (EF <40%), or prior MI 3, 1, 2
• Beta-blocker mandatory for post-MI patients or those with heart failure 3, 1

Symptom Control: Stepwise Anti-Anginal Algorithm

Step 1: Beta-Blocker Monotherapy (First-Line)

• Start beta-blocker (bisoprolol 10 mg once daily, metoprolol CR 200 mg once daily, or atenolol 100 mg daily) 1, 4
• Target resting heart rate 55–60 bpm for optimal symptom control 1
• Titrate to maximum tolerated dose before adding second agent 1, 4
• Contraindications: severe COPD, sinus bradycardia, AV block >1st degree, sick sinus syndrome 1

Step 2: Add Dihydropyridine Calcium Channel Blocker

• If beta-blocker alone insufficient, add long-acting dihydropyridine CCB (amlodipine 5–10 mg daily) 1, 2, 4
• This combination has strongest evidence for additive anti-anginal benefit 2
• Alternative: If beta-blocker contraindicated, substitute with non-dihydropyridine CCB (verapamil or diltiazem) OR long-acting nitrate 1, 4

Step 3: Consider Third Agent (Rarely Needed)

• Ranolazine may be added for refractory symptoms, particularly microvascular angina 1
• Warning: Three-drug regimens may provide less symptomatic protection than optimized two-drug therapy 1, 4

Acute Symptom Relief (All Patients)

• Sublingual nitroglycerin 0.3–0.6 mg for immediate relief (onset 1–7 minutes) and situational prophylaxis 3, 1, 2, 4
• Critical teaching point: Angina unresponsive to nitroglycerin = possible MI, seek emergency care immediately 3, 4

Critical Medication Pitfalls to Avoid

• Never use short-acting dihydropyridine CCBs (immediate-release nifedipine) without concurrent beta-blocker—increases adverse cardiac events 1, 2, 4
• Never combine verapamil or diltiazem with beta-blockers in heart failure patients—negative inotropic effects 1
• Never combine ivabradine with non-dihydropyridine CCBs or strong CYP3A4 inhibitors 1
• Avoid dipyridamole—worsens exercise-induced ischemia 2
• Avoid chelation therapy—no proven benefit 2
• Long-acting nitrates require 10–14 hour nitrate-free interval to prevent tolerance 2
• Never stop beta-blockers abruptly—taper over 4 weeks to avoid rebound angina 2

Risk Factor Modification (Evidence-Based Targets)

• Smoking cessation—single most impactful modifiable risk factor 1, 2
• Blood pressure <130/85 mmHg, especially with metabolic syndrome 2
• Strict glycemic control in diabetics with regular fasting glucose monitoring 2
• Aerobic exercise: 150–300 min/week moderate intensity or 75–150 min/week vigorous intensity 1
• Weight reduction for elevated waist circumference 2

Indications for Coronary Angiography & Revascularization

Refer for angiography when:

• Symptoms uncontrolled despite two optimally-dosed anti-anginal drugs 1, 4
• Severe angina (CCS class III–IV) persists on optimal medical therapy 1
• Non-invasive testing shows high-risk ischemia (≥10% LV myocardium) 1

Revascularization reduces mortality in:

• Left main stenosis ≥50% 1
• Three-vessel disease, especially with LV dysfunction 1
• Two-vessel disease with proximal LAD stenosis 1

PCI improves symptoms but not mortality in anatomically suitable lesions when medical therapy fails 3, 1

Follow-Up Protocol

• Every 4–6 months first year, then annually if stable 2
• At each visit assess: angina frequency/severity, medication adherence, risk factor control, new comorbidities 2
• Physical exam: weight, BP, pulse, JVP, carotid/pulmonary auscultation, cardiac exam for new murmurs/HF signs 2
• No routine periodic testing without clinical status change 2
• Repeat ECG when initiating/adjusting conduction-affecting drugs or angina pattern changes 2
• Stress testing only for significant clinical status change in non-revascularized patients 2